Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0017168 (gastroesophageal reflux disease)
 11,783 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The prescription of peritoneal dialysis should be individualized based on parameters of tolerance and adequacy. Determination of the intraperitoneal fill volume is essential for optimal patient care. Fill volume enhancement is a factor of exchange surface area recruitment: the wetted, contact peritoneal dialysis membrane. Nevertheless, fill volume enhancement can also lead to patient discomfort, with the potential risk of too high an intraperitoneal pressure (hernia, gastro-esophageal reflux). The perception of the individual patient is also a subjective parameter of fill volume tolerance assessment. In contrast, measurement of the hydrostatic intraperitoneal pressure (IPP, cmH(2)O) allows an objective approach to fill volume tolerance. From our clinical experience of more than 10 years of IPP measurements in child care, we can give a recommendation for normal values in children: less than 18 cm of water, usually between 5 and 15 cm, correlated to the intraperitoneal fill volume (naturally), but individually taking into account age, gender, "accustomization" and overall body mass index.
 ...
PMID:Measurement of hydrostatic intraperitoneal pressure: a useful tool for the improvement of dialysis dose prescription. 1289 79

Retrospective research carried out by 29 General Practitioners in their databases, in order to evaluate the prevalence of gastro-esophageal reflux disease in its different clinical outbreaks and the incidence of new diagnosis in the last quinquennium, the diagnostic approach through instrumental examinations (endoscopy) or empirical tests (PPI test), and the therapeutical aspects, in particular concerning the usage of PPI. The prevalence has been of 3.82%, while the data concerning the incidence have pointed out a progressive increase of the diagnosis in the last quinquennium, specially for the atypical outbreaks. Moreover, it has been noted a likely excessive use of endoscopy, in the follow up as well, while less used is the IPP test. Gastroesophageal reflux disease is the most important item in the expenditure for the usage of IPP.
 ...
PMID:[Peer review about gastro-esophageal reflux disease in primary care: epidemiology, diagnostic and therapeutic management]. 1667 Dec 71

Eosinophilic esophagitis is a recently identified disease. The histological examination of esophageal biopsies is essential for its diagnosis, which is made with steadily increasing frequency. Eosinophilic esophagitis is an anatomoclinical entity, involving both children and adults, characterized by a dense and isolated infiltration of the esophageal mucosa by eosinophils, revealed by clinical symptoms of upper digestive tract origin and resistant to anti-acid treatment with IPP at high doses. Eosinophilic esophagitis is currently interpreted as an allergic disease, even though its pathogenesis remains unclear. The disease has a chronic course with persistent or relapsing symptoms, present with symptoms similar to those of gastro-esophageal reflux or with dysphagia. Endoscopic examination shows the presence of characteristic, but not pathognomonic, lesions (stenoses, strictures, circular rings, reduction of calibre, white specks, granularity of the mucosa). The histological diagnosis requires multiple biopsies taken all along the esophagus. The main sign is the presence of a dense eosinophilic infiltrate of the mucosa: a peak density of more than 15 eosinophils in at least one x400 field is the minimal criteria required for diagnosis. Associated lesions correspond to tissue damage and repair secondary to eosinophil activation (basal hyperplasia, microabscesses, fibrosis of the lamina propria). The treatment is based on dietary measures (allergen exclusion) and on the use of anti-inflammatory drugs, mainly corticoids. In conclusion, eosinophilic esophagitis is an emerging disease, important to identify, since it requires a specific treatment, different from that of reflux esophagitis.
 ...
PMID:[Eosinophilic esophagitis: an "emerging disease"]. 1855 51

In most of cases treatment of gastroesophageal reflux disease (GERD) is not an issue. However, some 20% of patients complain of persisting symptoms despite IPP therapy. The reasons of this condition are still under studies. The most attention is paid to a nonacid reflux as a cause of these health discomforts. It is a type of GERD where pH of refluxate > 4.0. This group of patients can be selected thanks to a new diagnostic form, called multichannel intraluminal impedance. The correlation of symptoms, such as episodes of nonacid reflux, the mechanism of its genesis, and treatment potentials are still under persistent studies. It is too early a stage to jump into final conclusions. Researches that are carried on suggest that the main symptoms of this disease are regurgitations, chronic cough or other atypical symptoms. Thanks to the new diagnostic method, i.e., multichannel intraluminal impedance, and promising results of endoscopic and surgical treatments, a new solution of helping patients suffering with this disease is being introduced.
 ...
PMID:[Gastroesophageal reflux disease--nonacid reflux]. 1894 41

The otolaryngological symptoms during gastro-oesophageal reflux disease may be very frequent. When the global estimation in the literature go round 20%, the prevalence in the African studies is variable, between 4 and 43 %. The most common disease encountered are laryngitis and pharyngitis's manifestations. When it is not possible to perform the oesophageal pH-metry, the most sensitive examination in gastro-oesophageal reflux, endoscopic examination and therapeutic test with IPP can be proposed to any patient with ENT symptoms and manifestations of gastro-oesophageal reflux.
 ...
PMID:[The otolaryngological manifestations of gastroesophageal reflux disease]. 1963 50